In early findings, the antibody drug conjugate created strong responses in multiple tumor types where patients have unmet need. Trastuzumab deruxtecan, already used in to treat patients with breast, ...

Women diagnosed with advanced triple-negative breast cancer who cannot receive immunotherapy now have a new first-line ...

Daiichi Sankyo and AstraZeneca’s new application is based on the TROPION-Lung05 phase 2 trial and supported by data from additional trials including TROPION-Lung01 Previously submitted BLA based on ...

Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...

Patritumab deruxtecan showed no overall survival benefit over chemotherapy in EGFR mutation-positive NSCLC patients. The drug demonstrated a slight progression-free survival advantage and higher ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Topline overall survival (OS) results from the TROPION-Lung01 phase 3 trial, which previously met the dual primary endpoint of progression-free survival ...

SAN DIEGO -- Treatment with raludotatug deruxtecan (R-DXd) led to an "exciting" response rate among patients with heavily pretreated, platinum-resistant advanced ovarian cancer, according to an ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The DESTINY-Breast12 trial revealed that trastuzumab deruxtecan (T-DXd) effectively targets brain metastases in HER2-positive breast cancer. With a median progression-free survival of 17.3 months and ...

1.1 Trastuzumab deruxtecan is recommended for use within the Cancer Drugs Fund as an option for treating HER2‑positive unresectable or metastatic breast cancer in adults after 2 or more anti‑HER2 ...